AgingResearch.NewsJoin free

MimiVax

CompanyUnited States

MimiVax develops one asset, in phase 2 (SurVaxM in glioblastoma). Mostly vaccine acting on apoptosis and BIRC5; based in the United States.

1
Asset
Furthest stage
Phase 2
0
Trials
1
Signal

Pipeline

1

  • SurVaxM

    Vaccine targeting survivin (BIRC5) to stimulate an anti-tumor immune response.

    Phase 2, Vaccine, Apoptosis, BIRC5, glioblastoma, newly diagnosed glioblastoma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals1
  • Similar companies4

Intelligence